Long Term Safety and Survival in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH)

被引：0
|
作者：
Behr, J. [1 ,2 ]
Nathan, S. D. [3 ]
Harari, S. [4 ,5 ]
Wuyts, W. [6 ]
Kirchgaessler, K. [7 ]
Bengus, M. [7 ]
Gilberg, F. [7 ]
Alvaro, G. [7 ]
Wells, A. U. [8 ]
机构：
[1] Comprehens Pneumol Ctr, Dept Internal Med 5, Munich, Germany
[2] German Ctr Lung Res, Munich, Germany
[3] Inova Fairfax Hosp, Inova Heart & Vasc Inst, Falls Church, VA USA
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[5] Osped San Giuseppe, Dept Med, MultiMed IRCCS, Milan, Italy
[6] Univ Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1859
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH)
    Behr, J.
    Nathan, S. D.
    Wuyts, W. A.
    Bishop, N.
    Bouros, D. E.
    Antoniou, K.
    Guiot, J.
    Kramer, M. R.
    Kirchgaessler, K.
    Bengus, M.
    Gilberg, F.
    Perjesi, A.
    Harari, S.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Results of a Responder Analysis
    Harari, S.
    Nathan, S. D.
    Behr, J.
    Wuyts, W. A.
    Kirchgaessler, K.
    Bengus, M.
    Gilberg, F.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [3] PULMONARY ARTERIAL-HYPERTENSION (PH) AND PULMONARY HEMODYNAMICS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    TANAKA, S
    NAGAI, S
    KITAICHI, M
    IZUMI, T
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A594 - A594
  • [4] The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
    Valeyre, Dominique
    Albera, Carlo
    Bradford, Williamson
    Costabel, Ulrich
    King, Talmadge
    Noble, Paul
    Sahn, Steven
    du Bois, Roland
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [5] Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Impact on Health-Related Quality of Life
    Wuyts, W. A.
    Nathan, S. D.
    Wells, A. U.
    Harari, S. A.
    Samara, K.
    Bengus, M.
    Gilberg, F.
    Behr, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [6] Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
    Takaiwa, Takuya
    Tachibana, Hiromasa
    Arita, Machiko
    Ishida, Tadashi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [7] Prevalence of Pulmonary Arterial Hypertension (PAH) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Villar, Adolfo
    Ancochea, Julio
    Xaubet, Antonio
    CHEST, 2014, 145 (03)
  • [8] SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): LONG-TERM GLOBAL PHARMACOVIGILANCE DATA
    Lasky, Joseph
    Criner, Gerard
    Lazarus, Howard
    Kohlbrenner, Veronika
    Bender, Shaun
    Richeldi, Luca
    CHEST, 2019, 156 (04) : 1011A - 1012A
  • [9] Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
    Takaiwa, Takuya
    Tachibana, Hiromasa
    Arita, Machiko
    Ishida, Tadashi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [10] The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis
    Nadrous, HF
    Pellikka, PA
    Krowka, MJ
    Swanson, KL
    Chaowalit, N
    Decker, PA
    Ryu, JH
    CHEST, 2005, 128 (06) : 616S - 617S
12345